ADGRE5 and acute myeloid leukemia: As shown in Fig. 6B, low expression of LOC646762 predicted a poor prognosis, while high expression of CCND3, CBR1, C10orf54, CD97 and BLOC1S1 indicated adverse outcomes in AML patients.